Your email has been successfully added to our mailing list.

×
0.00050251256281397 0.00050251256281397 0.000251256281406985 0.000879396984924537 0.00201005025125624 0.00854020100502513 0.0090427135678391 0.00665829145728645
Stock impact report

RemeGen candidate Fast Track'd for lupus [Seeking Alpha]

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
Company Research Source: Seeking Alpha
The FDA has signed off onFast Track statusRemeGenRC18Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.SLE-related tickers: GlaxoSmithKline (GSK-1.9%MNK-3.4%BIIB-2.1%OTCQX:RHHBY-1.3%NKTR-6.0%HOTH-2.2%AZN-1.8%KZR-6.5%CRBP-0.3%LLY-0.6%INCY-0.8%XNCR-8.6%JNJ Show less Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for GSK alerts
Opt-in for
GSK alerts

from News Quantified
Opt-in for
GSK alerts

from News Quantified